pharmaphorum

APRIL 7, 2021

billion DKK ($672 million) from AbbVie after the companies struck an R&D deal to research epcoritamab, a bispecific antibody targeting CD3 and CD20 that the biotech developed in-house. Genmab has four technology platforms to draw from, with the most established being bispecific antibodies which target two receptors at once.

Antibody 91

Antibody Life Science Development Regulation 91

XTalks

JANUARY 17, 2024

In this Xtalks Spotlight edition, Xtalks spoke with two oncology clinical research experts from Fortrea , Laura Vidal, MD, Medical Head of Oncology, EU (European Union), and Ken Morrison, PhD, Global Head of Strategic Delivery & Growth Oncology.

Clinical Trials 124

Clinical Trials Clinical Trials Trials Gene Therapy 124

XTalks

MARCH 20, 2024

When it comes to leadership in clinical trials today, what qualities are necessary to navigate the evolving landscape of clinical research effectively? Xtalks recently had the opportunity to discuss Enciso’s journey in the clinical research industry and her decision to join Regeneron.

Clinical Trials 52

Clinical Trials Clinical Trials Trials Clinical Research 52

The Pharma Data

NOVEMBER 1, 2020

Clinical Data Expected by End of Year. Tiziana Life Sciences plc. (“Tiziana” or the “Company”). This clinical trial will be coordinated by the team at the INTRIALS, a leading, full-service Latin America Clinical Research Organization (CRO), based in Sao Paulo City, Brazil.

Clinical Trials 52

Clinical Trials Clinical Trials Antibody Life Science 52

Drug Discovery World

OCTOBER 16, 2023

Alchemab, on the other hand, has developed a highly differentiated platform which enables the identification of novel drug targets and therapeutics by analysis of patient antibody repertoires, drawing from the expertise in Cambridge to progress the company’s mission to build a broad pipeline of protective therapeutics for hard-to-treat diseases.

Drugs 75

Drugs Life Science Gene Therapy Genome 75

Crucial Data Soutions

NOVEMBER 9, 2021

CDS), a provider of innovative software to advance clinical research, announced today a new functionality on their mobile app, TrialKit, that enables people to self-enroll in global patient registries and participate in research directly from their smartphone or tablet. “We’re

Antibody 40

Antibody Clinical Trials Clinical Trials Life Science 40

Drug Discovery World

OCTOBER 20, 2022

While the number of antibody drugs sold in Japan is on the rise, approximately 90% of the products are manufactured overseas, indicating a high degree of dependence on overseas manufacturing bases.” . Academia and research . Similarly, biosimilars are expected to grow. Eisai and Biogen’s anti-amyloid beta (A?)

Development 52

Development Drugs Life Science Marketing 52

XTalks

JULY 14, 2022

Over time, even the use of Krystexxa can lead to the development of antibodies against it, reducing its effectiveness. Early data also showed that methotrexate could prevent the formation of anti-drug antibodies. This is why methotrexate was paired with it, as methotrexate is used to treat inflammatory conditions like arthritis.

FDA Approval 105

FDA Approval Antibody Trials Drugs 105

XTalks

MAY 17, 2024

XTALKS CLINICAL EDGE: Issue 2 — Calliditas interview Xtalks Clinical Edge is a magazine for clinical research professionals and all who want to be informed about the latest trends and happenings in clinical trials.

Development 52

Development Drugs Clinical Trials Clinical Trials 52

The Pharma Data

DECEMBER 17, 2020

Goater is CEO at Surface Oncology, an immuno-oncology company developing next-generation antibody therapies. Martin Carter Professor in Clinical Investigation and Head of the Laboratory of Investigative Dermatology at The Rockefeller University and Weinblatt is the co-director of Clinical Rheumatology at the Brigham and Women’s Hospital.

Development 52

Development Gene Therapy Engineer Life Science 52

Drug Discovery World

DECEMBER 8, 2023

Furthermore, the insights gleaned from the initial clinical trial data emphasise the importance of establishing pragmatic anticipations regarding the extent of improvement that AI will offer so you can create realistic goals. Equally vital is the need for transparent validation processes encompassing both in silico and in vitro methodologies.

Gene Therapy 64

Gene Therapy Gene In-Vitro Development 64

The Pharma Data

NOVEMBER 5, 2020

Prior to Lonza, she led External Science and Partnering across the globe for Sanofi R&D. Previously, he was an associate director at Navigant Life Science Consulting. O’Day has been a principal investigator for more than 200 clinical trials. Schollmeier is managing director of a consulting and investment firm. .

Genome 40

Genome Genomics Medicine Life Science 40

XTalks

DECEMBER 4, 2020

Since CKD is a broad diagnosis that can have a variety of underlying causes, a beneficial focus of current research strategies has been to identify biomarkers and develop diagnostics that can help stratify patients into clinically relevant categories and help guide their management. Study Design for Chronic Kidney Disease Trials.

Trials 52

Trials Clinical Trials Clinical Trials Antibody 52

Drug Discovery World

APRIL 29, 2024

Bill Dawson, Chair, Medicines Manufacturing Industry Partnership (MMIP): Dawson is Head of Biologics and Devices Manufacturing at GSK and has over 25 years’ experience in the vaccines, biopharma, pharmaceutical and clinical research (CRO) industries.

Drugs 52

Drugs Sales Gene Therapy Life Science 52

XTalks

NOVEMBER 7, 2022

“Liquid biopsies have demonstrated promising activity in multiple clinical settings, but the great enthusiasm and expectations around them can be harmful if not adequately managed,” said Dr. El Mustapha Bahassi, PhD, Director, Clinical Laboratory Sciences, at the global clinical research organization (CRO) Medpace.

Clinical Trials 98

Clinical Trials Clinical Trials Trials FDA Approval 98

XTalks

SEPTEMBER 17, 2020

While clinical researchers occasionally need to identify and validate a new surrogate endpoint for a given trial, choosing endpoints that have been previously used as the basis of NDAs and BLAs can clear the path to eventual approval. Primary Hyperoxaluria Type 1 (PH1). Prevalence: 1 to 3 in 1 million.

Trials 98

Trials Gene Hormones Clinical Trials 98

XTalks

AUGUST 30, 2022

Clinical research experts from the CRO Medpace shared insights about the operational and regulatory considerations for neuroscience trials with direct CNS administration. Such therapies may involve small interfering RNA (siRNA) or oligonucleotides in viral transfection platforms, large molecules and antibodies.

Trials 83

Trials Drug Delivery Drugs Gene 83

Drug Discovery World

AUGUST 10, 2022

Until about 25 years ago, the best treatment option for someone with blood cancer was either toxic radiation and chemotherapy or a bone marrow transplant that posed additional life-threatening risks to the patient 1. Next, the advent of antibody treatments in 1997 created the first targeted cancer therapy 2. Marwan obtained his M.S.

Manufacturing 98

Manufacturing Gene Genome Genomics 98

XTalks

FEBRUARY 13, 2023

Radiopharmaceutical therapy (RPT) uses isotopes that are conjugated to tumor-targeting agents (such as peptides, antibodies and novel small molecules). Radionuclide-ligand conjugates, including radionuclides that are conjugated to antibodies or peptides, have been studied extensively.

Clinical Trials 52

Clinical Trials Clinical Trials Trials DNA 52

Drug Discovery World

FEBRUARY 6, 2023

Johannes Goll, Global Head of Emmes’ Biomedical Data Science and Bioinformatics department, explains how big data analytics can deliver improved therapies and bring clinical research one step close to realising the potential of personalised care.

Big Data 52

Big Data RNA Bioinformatics Vaccination 52

Drug Discovery World

OCTOBER 7, 2022

It is about going faster in progressing our innovation to market, taking things further along the value chain as we de-risk the early science. It’s about working together with our partners in the life science sector to get world class innovations to patients. . RA: What’s the future outlook for Cancer Research Horizons?

HR 52

HR Research Drugs Development 52

XTalks

SEPTEMBER 14, 2020

Moderna, for one, recently reported positive results in older adults between 56 and 71, as well as those 71 years of age and older, who reportedly mounted levels of neutralizing antibodies against the SARS-CoV-2 virus after two doses of its vaccine that were comparable to those seen in younger adults. Johnson & Johnson’s COVID-19 Vaccine.

Vaccination 92

Vaccination Vaccine Antibody Life Science 92